Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 601 to 610 of 2440 total matches.
Baricitinib (Olumiant) for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
nib Olumiant: oh loo’ mee ant
Table 1. Pharmacology
Class Janus kinase (JAK) inhibitor
Formulation ...
The FDA has approved the Janus kinase (JAK) inhibitor
baricitinib (Olumiant – Lilly) for oral treatment of adults
with moderately to severely active rheumatoid arthritis
(RA) that has not responded adequately to one or more
tumor necrosis factor (TNF) inhibitors. Baricitinib is
the second JAK inhibitor to be approved for treatment
of RA; tofacitinib (Xeljanz, Xeljanz XR) was the first.
Lofexidine (Lucemyra) for Opioid Withdrawal
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
.1 It is comparable
in efficacy to the full opioid agonist methadone, but it
is safer and does ...
The FDA has approved lofexidine (Lucemyra – US
WorldMeds/Salix), a centrally acting alpha2 receptor
agonist, to manage withdrawal symptoms in adults
abruptly stopping opioid use. Available in the UK since
1992, lofexidine is the first nonopioid to be approved
in the US for management of opioid withdrawal
symptoms. Clonidine (Catapres, and generics), another
central alpha2 receptor agonist, has been used off-label
for this indication for many years.
Two New Drugs for Glaucoma
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
effective and may be better tolerated. The
0.1% formulation of the drug is better tolerated than
higher ...
The FDA has approved two new ophthalmic drugs for
reduction of intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension: latanoprostene
bunod (Vyzulta – Bausch and Lomb), a modified
prostaglandin analog, and netarsudil (VRhopressa – Aerie),
the first Rho kinase inhibitor to be approved in the US.
Firvanq - Vancomycin Oral Solution
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
1. SN Bass et al. Comparison of oral vancomycin capsule and
solution for treatment of initial ...
The FDA has approved vancomycin oral solution
(Firvanq – Cutis Pharma) for treatment of Clostridium
difficile-associated diarrhea and enterocolitis caused
by Staphylococcus aureus, including methicillin-resistant
strains (MRSA).
Correction: Abuse-Deterrent Opioids
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
-deterrent opioids, the information on
Targiniq ER in Table 1 is incorrect. The drug, which is not available ...
In our article on abuse-deterrent opioids (Med Lett Drugs Ther 2017; 59:95), the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available in the US, is a combination of oxycodone ER and naloxone, not naltrexone, and naloxone is dispersed throughout the tablet, not sequestered. Targiniq ER will be deleted from the table in the article as it appears on our website.
Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
-cell precursor
acute lymphoblastic leukemia (ALL) in patients ≤25
years old,1 was recently also ...
The FDA has approved axicabtagene ciloleucel
(Yescarta – Kite) for treatment of adults with relapsed
or refractory CD19+ large B-cell lymphoma after ≥2
lines of systemic therapy. Yescarta is an individualized
cellular product prepared from the patient's own T cells,
which are genetically modified to express chimeric
antigen receptors (CAR) and then infused back into
the patient. It is the second CAR T-cell immunotherapy
to become available in the US. Tisagenlecleucel
(Kymriah), a CAR T-cell product previously approved
for treatment of relapsed or refractory B-cell...
Apalutamide (Erleada) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
with
apalutamide and was 39 months with placebo.1
Enzalutamide (Xtandi), an androgen receptor inhibitor ...
Apalutamide (Erleada – Janssen) has received
accelerated approval from the FDA for treatment of
nonmetastatic castration-resistant prostate cancer.
It is the first drug to be approved in the US for this
indication. Apalutamide is an oral antiandrogen that
binds to the ligand-binding domain of the androgen
receptor.
Erenumab (Aimovig) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
preventive treatment.1,2
Beta blockers and antiepileptic drugs are commonly
used for prevention of migraine ...
The FDA has approved erenumab-aooe (Aimovig –
Amgen/Novartis), a once-monthly, subcutaneously-injected,
monoclonal antibody against the calcitonin
gene-related peptide receptor, for preventive treatment
of migraine in adults. It is the first drug in its class to
be approved by the FDA.
Andexxa - An Antidote for Apixaban and Rivaroxaban
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
for reversal of the anticoagulant
effect of the direct thrombin inhibitor dabigatran
etexilate (Pradaxa).1 ...
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor Xa
inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto).
Andexanet alfa is the second antidote for a direct oral
anticoagulant to become available in the US, and the
fi rst for factor Xa inhibitors. Idarucizumab (Praxbind)
was approved in 2015 for reversal of the anticoagulant
effect of the direct thrombin inhibitor dabigatran
etexilate (Pradaxa). Andexanet alfa has not...
Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
Vabomere: vay' boh mere
Vaborbactam: vab" or bak' tam
Table 1. Pharmacology
Class Carbapenem/beta ...
The FDA has approved a fixed-dose combination of
meropenem, a carbapenem antibiotic, and vaborbactam,
a new beta-lactamase inhibitor (Vabomere – Melinta),
for IV treatment of adults with complicated urinary
tract infections (UTIs) that are proven or strongly
suspected to be caused by Escherichia coli, Klebsiella
pneumoniae, or Enterobacter cloacae spp. complex.
Meropenem (Merrem, and generics) has been approved
for years for treatment of complicated skin and skin
structure infections, intra-abdominal infections, and
bacterial meningitis. Resistance to meropenem and
other...